Casimersen Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/ml
Reference Brands: Amondys 45 (USA)
Category:
Neurology
Casimersen is available in Injection
and strengths such as 50 mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Casimersen is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Casimersen can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Casimersen, marketed under the brand name Amondys 45, is an antisense oligonucleotide medication specifically designed for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. It is a phosphorodiamidate morpholino oligomer (PMO) that targets dystrophin pre-mRNA, enabling the cellular machinery to skip the defective exon and produce a shortened but functional dystrophin protein.
Duchenne muscular dystrophy is a rare, progressive genetic disorder that primarily affects boys and is characterized by the absence or deficiency of dystrophin, a critical protein for muscle integrity and function. The lack of dystrophin leads to progressive muscle weakness, loss of mobility, and reduced life expectancy. Casimersen offers a targeted therapeutic approach by addressing the underlying genetic defect, aiming to slow disease progression and improve muscle function. The medication is administered via intravenous infusion under strict medical supervision, with treatment tailored to the patient’s specific genetic mutation and clinical condition.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing